Daily rimegepant, atogepant vs topiramate, and a propranolol recall
Hi, it's Cerebral Torque. Here's what happened in migraine research this week, what each study found, and how much weight I'd give it. Two of these touch medicines a lot of you take, so they're up top.
The ones that matter most
Rimegepant (Nurtec ODT) worked better taken every day
Rimegepant is approved for prevention every other day. In a 692-person trial, taking it once daily cut 1.8 more monthly migraine days than placebo, while every other day cut 0.6 more. The trial wasn't built to compare the two schedules head to head, and several authors work for Pfizer, which makes it. If every-other-day dosing isn't doing much for you, this is a fair thing to raise with your clinician. Read my breakdown
Atogepant (Qulipta) beat topiramate (Topamax) on side effects
In the 545-person TEMPLE trial, 12 percent of people on atogepant stopped because of side effects, compared with 30 percent on topiramate. 64 percent on atogepant had their migraine days cut at least in half, compared with 39 percent on topiramate. AbbVie funded it and topiramate was capped at 100 mg a day, and topiramate still helped plenty of people, so cost and pregnancy plans still count. Read my breakdown
If atogepant works in month one, it usually keeps working
Pooling two trials, 61 to 74 percent of people whose migraine days dropped by half in the first month kept that through month three. Of those responding at month four, 83 to 89 percent still were at one year. This was an AbbVie analysis without a placebo comparison, but it's reassuring for anyone off to a good start. Read my breakdown
Migraine plus smoking raised early stroke risk more than either alone
In 1.68 million Danish women followed to age 60, ischemic stroke occurred in 0.8 percent of women with neither, 1.3 percent with migraine, 1.5 percent who smoked, and 2.8 percent with both. Together, the risk was more than the two added up. It's an association from a registry, but if you have migraine and smoke, this is one of the strongest reasons to stop. Read my breakdown
Also this week
- A second CGRP drug still helped about 3 in 10. In 254 people with hard-to-treat migraine in Spain, 61 percent of first CGRP treatments cut migraine days in half at six months, compared with 29 percent of second or later ones. Lower, but not nothing. Small and single-center. Details
- Migraine with aura and stroke after a hospital stay. In US hospital data, people admitted with migraine with aura had about twice the risk of coming back with an ischemic stroke within 90 days. Migraine without aura showed no clear link. It's an association, and it only covers people sick enough to be admitted. Details
- Online CBT helped disability, not migraine days. In a 154-person Swedish trial, adding a guided online therapy program lowered migraine-related disability at 12 months, but migraine days and pain didn't change. Useful for coping, not a preventive on its own. Details
- Spanish specialists on how long prevention should last. A consensus of headache specialists recommends prevention at four or more migraine days a month with real impact on your life, and continuing it for at least 12 months after you reach good control. Details
- Botox around conception. A review of 143 pregnancies found no more problems than general US rates, but most of the evidence came from case reports, so it can't rule much out. Details
News
Propranolol extended-release recall. On November 16, Breckenridge recalled one lot of generic propranolol (Inderal) extended-release 60 mg capsules over possible metal pieces. It's narrow, one lot of one strength from one company, but if you take that strength, check your bottle. How to check yours
New on the site
Every topic page now has a short guide and answers to the most common questions, from prevention to accommodations and insurance. And Today in Migraine Science still covers new studies every day if a week is too long to wait.
That's the week. Hit reply if a study raised a question for you. I read every reply.
Cerebral Torque
Cerebral Torque stays free with no ads because readers buy CROWN or the book. Thank you if you're one of them.
Get this every Friday
The week's migraine studies and news, explained in plain language. No ads, and one click to unsubscribe.
This is education, not medical advice. Talk with your own clinician before starting, stopping or changing any treatment.